Close Menu

NEW YORK (GenomeWeb) — Centogene said today that it has entered a 12-month strategic collaboration with Sarepta Therapeutics for the identification of patients with Duchenne muscular dystrophy in the Middle East and North Africa.

Under the terms of the agreement with Sarepta, Centogene will provide diagnostic services to physicians treating patients exhibiting symptoms related to DMD.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.